Back to search results

Trial Evaluating AMG 127 for Type 2 Diabetes Mellitus

This study is testing a drug called AMG 127 to see how safe it is and how well people tolerate it. It's being given as either a shot under the skin (subcutaneous injection) or through a vein (intravenous infusion). The study includes both healthy volunteers and people with type 2 diabetes. Researchers will compare AMG 127 to a placebo (an inactive substance) to understand any side effects. The main goal is to track any adverse events (unwanted medical problems) that happen during the study. This trial is currently unclear about its recruitment status and plans to enroll 162 participants.

Study design
This interventional study plans to enroll 162 participants. It involves giving either AMG 127 or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events for up to approximately 115 days after screening, depending on the study part.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07590193

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Recruiting
PHASE1Ages 18–75InterventionalTreatment
Amgen
~162 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:AMG 127Placebo

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Treatment-Emergent Adverse Events (TEAEs)
Measured over Part A, SAD: Day 1 to end of trial (up to approximately 58 days); Part B, MAD: Day 1 to end of trial (up to approximately 86 days); Part C, PoM: Day 1 to end of trial (up to approximately 87 days)
+2 more outcomes measured

Conditions

Diabetes Mellitus, Type 2

Explore related trials

Healthy VolunteersType 2 Diabetes Mellitus

NCT07590193

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Orange County Research Center

    Lake Forest, Californiano site contact published

    Recruiting

  • Translational Clinical Research LLC

    Aventura, Floridano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • MD · STUDY_DIRECTOR · Amgen

Who to contact

Amgen Call Center
[email protected]
866-572-6436
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must be 18-65 years of age
Participant must be overtly healthy
Participant must be 40-75 years of age
Confirmed diagnoses of T2DM

Exclusion

History of hypotension, syncope, or orthostatic intolerance
Systolic blood pressure \>140 millimeters of mercury (mmHg) or diastolic blood pressure \>90 mmHg
Hemoglobin A1c (HbA1c) \>10% within the last 3 months
History of hypotension, syncope, or orthostatic intolerance
Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg

What this trial measures

  • Number of Treatment-Emergent Adverse Events (TEAEs)Part A, SAD: Day 1 to end of trial (up to approximately 58 days); Part B, MAD: Day 1 to end of trial (up to approximately 86 days); Part C, PoM: Day 1 to end of trial (up to approximately 87 days)
  • Number of Serious Adverse Events (SAEs)Part A, SAD: Screening to end of trial (up to approximately 86 days); Part B, MAD: Screening to end of trial (up to approximately 114 days); Part C, PoM: Screening to end of trial (up to approximately 115 days)
  • Number of Adverse Events Leading to Study DiscontinuationPart A, SAD: Day 1 to end of trial (up to approximately 58 days); Part B, MAD: Day 1 to end of trial (up to approximately 86 days); Part C, PoM: Day 1 to end of trial (up to approximately 87 days)